- Home
- APGE vs SUPN Comparison
APGE vs SUPN Comparison
Compare APGE & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- SUPN
- Stock Information
- Founded
- APGE 2022
- SUPN 2005
- Country
- APGE United States
- SUPN United States
- Employees
- APGE N/A
- SUPN N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- APGE Health Care
- SUPN Health Care
- Exchange
- APGE Nasdaq
- SUPN Nasdaq
- Market Cap
- APGE 2.1B
- SUPN 1.7B
- IPO Year
- APGE 2023
- SUPN 2012
- Fundamental
- Price
- APGE $37.81
- SUPN $31.54
- Analyst Decision
- APGE Strong Buy
- SUPN Hold
- Analyst Count
- APGE 4
- SUPN 2
- Target Price
- APGE $91.33
- SUPN $36.00
- AVG Volume (30 Days)
- APGE 579.0K
- SUPN 422.3K
- Earning Date
- APGE 05-20-2025
- SUPN 05-06-2025
- Dividend Yield
- APGE N/A
- SUPN N/A
- EPS Growth
- APGE N/A
- SUPN N/A
- EPS
- APGE N/A
- SUPN 1.11
- Revenue
- APGE N/A
- SUPN $667,997,000.00
- Revenue This Year
- APGE N/A
- SUPN N/A
- Revenue Next Year
- APGE $743.14
- SUPN $9.14
- P/E Ratio
- APGE N/A
- SUPN $27.95
- Revenue Growth
- APGE N/A
- SUPN 11.82
- 52 Week Low
- APGE $26.20
- SUPN $25.53
- 52 Week High
- APGE $63.50
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- APGE 53.99
- SUPN 46.52
- Support Level
- APGE $36.59
- SUPN $29.16
- Resistance Level
- APGE $41.05
- SUPN $33.28
- Average True Range (ATR)
- APGE 2.25
- SUPN 1.20
- MACD
- APGE 0.15
- SUPN 0.04
- Stochastic Oscillator
- APGE 62.72
- SUPN 57.77
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.